← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #769 OF 1,000 MOST-CITED

Written record of complaint to include findings, follow-up

FDA cited this observation 21 times across 21 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs21
BY FISCAL YEAR
FY20252
FY20231
FY20223
FY20202
FY20199
FY20182
FY20172

How FDA worded it — real examples

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

Microvascular Tissue, Inc · San Diego, California · Drugs · 2025-04-08

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

Elemental Herbs, Inc. · Morro Bay, California · Drugs · 2024-12-20

Written records of investigation of a drug complaint do not include the findings of the investigation.

Laboratorio Reig Jofre S.A. · Toledo · Drugs · 2023-06-23

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

Torrent Pharmaceuticals Limited · Indrad · Drugs · 2022-09-28

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

Hetero Labs Limited (Unit V) · Mahabubnagar · Drugs · 2022-08-12

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

CooperSurgical, Inc. · North Tonawanda, New York · Drugs · 2022-03-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →